10-Q: Merck's Q3 2025 Earnings Surge on Oncology, Cardiovascular Growth

Merck reported a significant increase in net income and EPS for Q3 2025, driven by strong performance in its oncology and cardiovascular franchises, despite declines in vaccines and virology.

Summary

• Net income attributable to Merck & Co., Inc. surged 83.2% to $5,785 million in Q3 2025, up from $3,157 million in Q3 2024.
• Diluted Earnings per Common Share increased by 87.1% to $2.32 in Q3 2025, compared to $1.24 in Q3 2024.
• Worldwide sales grew 4% to $17.3 billion in Q3 2025, with U.S. sales up 15% and international sales down 8%.
• Keytruda sales increased 10% in Q3 2025 to $8,142 million, driven by higher demand and net pricing in the U.S. and international markets.
• The company initiated a new $3.0 billion restructuring program in July 2025, expected to yield $1.7 billion in annual cost savings by the end of 2027.
• Cash provided by operating activities decreased to $13.6 billion for the first nine months of 2025, down from $18.0 billion in the same period of 2024.
• Merck acquired Verona Pharma plc for approximately $10.5 billion in October 2025, adding Ohtuvayre (ensifentrine) for COPD.
• The company issued $6.0 billion in senior unsecured notes in September 2025, partly to fund the Verona Pharma acquisition.
• Gardasil/Gardasil 9 sales declined significantly by 24% in Q3 2025 and 40% in the first nine months of 2025, primarily due to lower demand and a temporary pause in shipments to China.
• Lagevrio sales decreased 64% in Q3 2025 and 62% in the first nine months of 2025 due to declining COVID-19 cases.
• Januvia and Janumet sales grew 29% in Q3 2025, benefiting from higher U.S. net pricing, but face anticipated significant declines from 2026 due to patent expiries and IRA price setting.
• Merck's new RSV antibody, Enflonsia, received FDA approval in June 2025, with initial U.S. sales of $79 million in Q3 2025 from inventory stocking, but EC decision delayed due to a data entry issue.
• The company authorized an additional $10 billion for common stock repurchases in January 2025, with $8.6 billion remaining as of September 30, 2025.

Sentiment

Score: 8

Explanation: The filing indicates strong financial performance with significant increases in net income and EPS, driven by key oncology and cardiovascular products. Strategic acquisitions and restructuring initiatives position the company for future growth and efficiency. While there are challenges with certain vaccine sales and upcoming patent expiries for diabetes drugs, the overall pipeline progress, favorable legal resolutions, and proactive management of future risks contribute to a positive outlook.

Positives

• Net income attributable to Merck & Co., Inc. increased 83.2% to $5,785 million in Q3 2025.
• Diluted Earnings per Common Share rose 87.1% to $2.32 in Q3 2025.
• Worldwide sales increased 4% to $17.3 billion in Q3 2025, with U.S. sales up 15%.
• Keytruda sales grew 10% to $8,142 million in Q3 2025, driven by strong demand and net pricing.
• Welireg sales increased 42% in Q3 2025 due to higher demand in the U.S. and international launch uptake.
• Winrevair sales reached $360 million in Q3 2025 and $976 million in the first nine months of 2025, reflecting strong U.S. uptake and early EU launch.
• Capvaxive sales were $244 million in Q3 2025 and $480 million in the first nine months of 2025, driven by continued U.S. uptake and seasonal inventory build.
• Enflonsia received FDA approval in June 2025 for RSV prevention in infants, with initial U.S. sales of $79 million in Q3 2025 from inventory stocking.
• Positive topline Phase 3 results were announced for MK-0616 (enlicitide decanoate), a PCSK9 inhibitor for hyperlipidemia.
• The 2025 Restructuring Program is expected to generate approximately $1.7 billion in annual cost savings by the end of 2027.
• Merck acquired Verona Pharma plc for approximately $10.5 billion, adding Ohtuvayre for COPD.
• A funding arrangement with Blackstone Life Sciences will provide $700 million to fund development costs for MK-2870 (sac-TMT) in 2026.
• The Supreme Court denied certiorari for the Qui Tam and MMR II vaccine antitrust lawsuits, ending these matters favorably for Merck.
• The Federal Circuit affirmed Merck's favor in the Bridion patent litigation, securing U.S. exclusivity through July 27, 2026.
• H.R.1 One Big Beautiful Bill Act (OBBBA) delays Keytruda's eligibility for IRA government price setting until 2027 (effective Jan 1, 2029).
• Merck's proposed agreement to substantially resolve Gardasil product liability litigation for an amount "not material to Merck" and "considerably less than anticipated costs of defense."

Negatives

• Gardasil/Gardasil 9 sales declined 24% in Q3 2025 and 40% in the first nine months of 2025, primarily due to lower demand in China and Japan.
• Merck temporarily paused Gardasil/Gardasil 9 shipments to China from February 2025 and will not make further shipments through at least the end of 2025 due to elevated inventory levels.
• Lagevrio sales decreased 64% in Q3 2025 and 62% in the first nine months of 2025 due to declining COVID-19 cases.
• Simponi and Remicade sales declined 100% as marketing rights reverted to Johnson & Johnson on October 1, 2024.
• Dificid lost U.S. market exclusivity in July 2025, leading to a 55% sales decline in Q3 2025, with significant declines expected to continue.
• Bridion is expected to lose U.S. market exclusivity in July 2026, anticipating a significant sales decline thereafter.
• Januvia and Janumet are expected to face significant sales declines in the U.S. from 2026 due to patent expiries (May 2026 for Januvia/Janumet, July 2026 for Janumet XR) and government price setting under the IRA (Januvia effective Jan 1, 2026; Janumet/Janumet XR effective Jan 1, 2027).
• Cash provided by operating activities decreased by $4.4 billion to $13.6 billion for the first nine months of 2025 compared to the same period in 2024.
• Net increase in cash, cash equivalents and restricted cash decreased by $2.8 billion to $4.9 billion for the first nine months of 2025.
• The EC decision on marketing authorization for Enflonsia (RSV antibody) is delayed due to a data entry issue related to solicited complaints.
• The Phase 3 VICTOR trial for Verquvo did not meet its primary endpoint in HFrEF patients without a recent worsening heart failure event.
• Merck withdrew EU and UK marketing authorization applications for Ohtuvayre (ensifentrine) post-acquisition, with plans to resubmit at a future date.

Risks

• Global efforts toward health care cost containment continue to exert pressure on product pricing and market access worldwide.
• Changes to the U.S. health care system, including health care reform and increased purchasing power of entities negotiating on behalf of Medicare, Medicaid, and private sector beneficiaries, contribute to pricing pressure.
• The elimination of the statutory cap on Medicaid rebates (effective January 2024) negatively impacts company performance, as Merck paid more in rebates than it received for Januvia family products in 2024.
• The Inflation Reduction Act (IRA) introduces financial penalties for drugs whose prices rise faster than inflation, redesigns the Medicare Part D program (effective 2025), and implements government price-setting for certain Medicare Part D (starting 2026) and Part B (starting 2028) drugs.
• Government price setting under the IRA may negatively impact pricing in the private market.
• Increased utilization of the 340B Federal Drug Discount Program and restrictions on the company's ability to identify inappropriate discounts negatively impact performance.
• Future changes to tariffs, particularly potential U.S. tariffs on pharmaceutical products, could have an adverse effect on the company's business.
• The May 2025 executive order seeking a Most Favored Nation drug pricing policy could result in reduced prices and reimbursement for certain products in the U.S., with uncertain impact.
• The IRS issued Notices of Proposed Adjustment (NOPAs) in April 2025, proposing a $1.3 billion increase in one-time transition tax and $260 million in penalties, which Merck will vigorously contest, but an unsuccessful defense could be material to financial statements.
• Ongoing product liability lawsuits related to Dr. Scholls Foot Powder (talc/mesothelioma) and Gardasil/Gardasil 9 (POTS, other injuries).
• Governmental proceedings, including a Civil Investigative Demand from the U.S. DOJ regarding DEI programs and federal contract compliance, and inquiries from Chinese governmental agencies and international competition authorities.
• Securities litigation alleging violations of federal securities laws and breach of fiduciary duty related to Gardasil/Gardasil 9 demand in China.
• Patent litigation, including challenges to Bridion, Januvia/Janumet, Keytruda, subcutaneous pembrolizumab, Lynparza, and Capvaxive, which if adverse, could result in significantly shortened periods of exclusivity and potential intangible asset impairment charges.
• Manufacturing delays related to ProQuad and Varivax are anticipated to cause supply constraints in some international markets during 2025.
• The ACIP recommendation for standalone varicella immunization for children under four years, rather than combined MMRV, could negatively affect ProQuad sales (though anticipated to be immaterial).
• Competitive pressure in the vaccines market (e.g., Vaxneuvance in Japan) and companion animal products (parasiticides).
• The EC decision on marketing authorization for Enflonsia is delayed due to a data entry issue, which could impact its commercial availability.
• The 2025 Restructuring Program involves eliminating certain positions in sales, administrative, and R&D organizations, which could impact employee morale or operational continuity.
• The 2024 Restructuring Program involves closing or divesting manufacturing facilities, which could lead to disruptions or unforeseen costs.

Future Outlook

Merck anticipates significant sales declines for Januvia, Janumet, and Janumet XR in the U.S. from 2026 due to patent expiries and government price setting under the IRA. The company expects the pace of share repurchases to continue for the remainder of 2025. The 2025 Restructuring Program is projected to generate $1.7 billion in annual cost savings by the end of 2027, which will be fully reinvested into strategic growth areas. The global minimum tax provision of OECD Pillar 2 is expected to have an approximate 2% impact on the full year 2025 effective income tax rate. The EC decision on marketing authorization for Enflonsia is delayed, but Merck remains confident in its risk-benefit profile. The company expects tariffs implemented to date to result in less than $100 million of additional expenses in 2025.

Management Comments

• "Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report." (Robert M. Davis, CEO)
• "Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report." (Robert M. Davis, CEO & Caroline Litchfield, CFO)
• "The 2025 Restructuring Program is designed to position the Company for its next chapter of growth and to successfully advance its pipeline and launch new products across multiple therapeutic areas."
• "The Company will, however, continue to hire employees into new roles across all strategic growth areas of the business."
• "Merck remains confident in the robustness of the CLEVER and SMART trials as pivotal studies for Enflonsia and the risk benefit profile of Enflonsia."
• "The Company expects higher U.S. net sales of these products [Januvia family] for full year 2025 compared with full year 2024."
• "The Company expects the pace of share repurchases to continue at this level for the remainder of 2025."
• "The Company disagrees with the proposed adjustments [from IRS NOPAs] and will vigorously contest the NOPAs through all available administrative and, if necessary, judicial proceedings."
• "The Company intends to vigorously defend its patents, which it believes are valid, against infringement by companies attempting to market products prior to the expiration of such patents."
• "The Company believes the asserted patent [for Capvaxive] is invalid and not infringed."
• "In the opinion of the Company, either the likelihood of loss is remote or any reasonably possible loss associated with the resolution of such proceedings is not expected to be material to the Company’s financial condition, results of operations or cash flows either individually or in the aggregate." (Regarding other pending legal proceedings)

Industry Context

Merck's Q3 2025 performance reflects broader trends in the pharmaceutical industry, with strong growth in oncology and specialized therapies like Winrevair for PAH, indicating a shift towards high-value innovative medicines. The significant decline in COVID-19 related product sales (Lagevrio) is consistent with the global reduction in pandemic-driven demand. The challenges faced by Gardasil in China and Japan highlight the complexities of international market access and competition, including the emergence of local manufacturers. The impact of U.S. drug pricing legislation, such as the IRA, continues to be a major industry headwind, affecting key products like Januvia and Janumet, and driving strategic responses like list price adjustments and litigation. The company's substantial R&D investments and strategic acquisitions, such as Verona Pharma, are typical of large pharmaceutical players seeking to replenish pipelines and secure future growth drivers amidst patent cliffs and evolving market dynamics.

Comparison to Industry Standards

• Merck's 83.2% increase in Q3 2025 net income and 87.1% increase in diluted EPS significantly outperform many established pharmaceutical companies, which often report more modest single-digit or low-double-digit growth, especially for mature portfolios.
• Keytruda's 10% sales growth in Q3 2025 continues its strong performance, maintaining its position as a leading oncology blockbuster, comparable to the sustained growth seen in other top-tier PD-1/PD-L1 inhibitors from competitors like Bristol-Myers Squibb (Opdivo) or Roche (Tecentriq) in their prime, although Keytruda's scale is now larger.
• The rapid uptake of Winrevair ($976 million in 9M 2025) for Pulmonary Arterial Hypertension (PAH) demonstrates successful market penetration for a novel therapy, potentially setting a new benchmark for rare disease drug launches, similar to the initial success of therapies from companies like United Therapeutics or Johnson & Johnson in the PAH space.
• The substantial decline in Gardasil sales in China and Japan, coupled with the temporary pause in shipments, indicates a significant market access challenge that is more severe than typical regional fluctuations, potentially reflecting aggressive local competition or policy shifts, a risk factor that other vaccine manufacturers like GSK or Pfizer also navigate in emerging markets.
• The anticipated "significant sales declines" for Januvia and Janumet post-2026 due to patent expiries and IRA price negotiations is a common industry challenge, mirroring the "patent cliff" experiences of companies like Pfizer (Lipitor) or Eli Lilly (Cialis) in previous decades, requiring robust pipeline replenishment.
• The $10.5 billion acquisition of Verona Pharma for Ohtuvayre (COPD) is a substantial strategic move, comparable in scale and intent to recent mid-to-large biopharma acquisitions by peers like Pfizer's acquisition of Seagen or AbbVie's acquisition of ImmunoGen, aimed at bolstering specific therapeutic areas.
• The $3.0 billion restructuring program with $1.7 billion in annual cost savings by 2027 is a significant efficiency drive, aligning with similar large-scale operational optimization initiatives undertaken by global pharmaceutical companies to streamline operations and reinvest in R&D, such as those seen at Novartis or Sanofi.

Legal Proceedings

• Approximately 605 product liability cases are pending against Merck in various state courts related to Dr. Scholls foot powder, alleging exposure to asbestos-contaminated talc and development of mesothelioma.
• Approximately 135 product liability cases are pending against Merck in federal or state court related to Gardasil/Gardasil 9, alleging various personal injuries including postural orthostatic tachycardia syndrome (POTS).
• A U.S. Judicial Panel on Multidistrict Litigation ordered federal Gardasil/Gardasil 9 cases transferred for coordinated pre-trial proceedings, with Merck's motion for summary judgment granted in 16 bellwether cases (now appealed).
• A Gardasil product liability trial in California state court commenced on January 28, 2025, and was adjourned to February 2, 2026.
• Merck entered into a proposed agreement in October 2025 to substantially resolve the Gardasil product liability litigation for an amount "not material to Merck," subject to conditions.
• Merck received a Civil Investigative Demand (CID) from the U.S. Department of Justice (DOJ) in August 2025, pursuant to a False Claims Act investigation regarding the company's diversity, equity, and inclusion programs and practices.
• Ongoing inquiries from various Chinese governmental agencies regarding operations.
• Ongoing preliminary investigation activities from competition and other governmental authorities in markets outside the U.S.
• A putative class action, Cronin v. Merck & Co., Inc., et al., was filed on February 12, 2025, alleging violations of federal securities laws regarding demand for Gardasil/Gardasil 9 in China.
• Derivative lawsuits (Collins v. Davis, et al. and Daniel, et al. v. Frazier, et al.) were filed against certain Merck officers and board members, asserting claims of Section 14(a), breach of fiduciary duty, waste of corporate assets, and unjust enrichment based on similar allegations as the securities class action; these lawsuits are currently stayed.
• Another derivative lawsuit (Weniger, et al. v. Frazier, et al.) was filed in New Jersey state court with similar allegations.
• Zetia antitrust litigation involved settlements with direct purchaser, retailer, and indirect purchaser plaintiffs in 2023, while cases from Insurer Plaintiffs (United HealthCare, Humana, Centene, Kaiser) were remanded and are ongoing with motions to dismiss and third-party complaints filed.
• Qui Tam litigation regarding the M-M-R II vaccine, alleging fraud, was dismissed in Merck's favor by the district court in July 2023, affirmed by the Third Circuit in August 2024, and the Supreme Court denied certiorari in October 2025, ending the matter.
• MMR II vaccine antitrust lawsuits were resolved in Merck's favor, with the Supreme Court denying certiorari in October 2025, ending the matter.
• Patent infringement lawsuits are ongoing against generic companies seeking to market versions of Bridion, with U.S. exclusivity secured through July 27, 2026.
• Settlements have been reached with over two dozen generic companies for Januvia and Janumet, allowing market entry in May 2026, and Janumet XR in July 2026, although a non-automatically substitutable form of sitagliptin has been approved.
• A patent infringement lawsuit was filed in Tokyo District Court in October 2023 against Sawai Pharmaceuticals Co., Ltd. and Medisa Shinyaku Co., Ltd. regarding sitagliptin.
• Merck is involved in patent litigation with The Johns Hopkins University (JHU) concerning Keytruda, with the PTAB finding six of JHU's patents unpatentable, and the case stayed pending further PTAB decisions.
• Halozyme, Inc. alleges patent infringement by Merck's subcutaneous pembrolizumab product, leading to Merck filing post grant review petitions and revocation actions in multiple countries, with a preliminary injunction hearing scheduled in Germany for December 4, 2025.
• Patent infringement lawsuits are ongoing against generic companies seeking to market versions of Lynparza, with the earliest FDA approval date for generics being September 2027.
• Pogona, LLC filed a complaint in September 2025 alleging that Capvaxive infringes U.S. Patent No. 11,058,757, with Merck believing the patent is invalid and not infringed.

Stakeholder Impact

• Shareholders: Positive impact from increased net income and EPS, continued share repurchase program ($8.6 billion remaining authorization), and consistent dividend payments ($0.81 per share). Potential negative impact from anticipated sales declines for Januvia family post-2026 and potential adverse outcomes from IRS tax dispute or ongoing litigations.
• Employees: The 2025 Restructuring Program involves eliminating certain positions in sales, administrative, and R&D organizations, but the company plans to continue hiring in strategic growth areas. The 2024 Restructuring Program also involves headcount reductions and facility closures.
• Customers (Patients/Healthcare Providers): New product approvals and launches (Winrevair, Enflonsia, Capvaxive) offer new treatment options. Pricing pressures from government policies (IRA, Medicaid rebates) could affect drug access or affordability.
• Suppliers/Partners: Acquisitions (Verona Pharma, WuXi Vaccines facility) and collaborations (Blackstone, Hengrui Pharma, LaNova) indicate continued strategic engagement and investment in the ecosystem. The temporary pause in Gardasil shipments to China impacts distributors like Zhifei.
• Creditors: Issuance of $6.0 billion in senior unsecured notes increases long-term debt, but proceeds were used for strategic acquisitions. The company's strong cash position and operating cash flow provide financial stability.

Next Steps

• Merck to record a $150 million charge to Research and development expenses in Q4 2025 for the upfront payment to Dr. Falk Pharma GmbH for MK-8690.
• Falk is eligible to receive a developmental milestone payment and tiered low-single-digit royalties on sales of MK-8690.
• Merck is in the process of determining the fair value of assets acquired and liabilities assumed in the Verona Pharma acquisition.
• Blackstone Life Sciences will pay Merck $700 million to fund a portion of MK-2870 development costs throughout 2026.
• Blackstone will be eligible to receive low-to-mid single-digit royalties on net sales of sac-TMT upon U.S. regulatory approval for first-line triple-negative-breast cancer.
• Hengrui Pharma is eligible to receive future contingent developmental, regulatory, and sales-based milestone payments, as well as tiered royalties on future net sales of MK-7262.
• Merck may receive future payments of $150 million in January 2026 and January 2027, and $100 million in January 2028 from AstraZeneca for Koselugo, subject to annual election.
• Merck is eligible to receive future contingent regulatory milestones of up to $75 million and sales-based milestones of up to $235 million from AstraZeneca for Koselugo.
• Merck will record a $50 million regulatory milestone payment from AstraZeneca for Koselugo in Q4 2025.
• Merck will continue to hire employees into new roles across all strategic growth areas of the business as part of the 2025 Restructuring Program.
• Most actions under the 2025 Restructuring Program are expected to be largely completed by the end of 2027, with certain manufacturing actions by the end of 2029.
• The 2025 Restructuring Program is anticipated to achieve $1.7 billion in annual cost savings by the end of 2027, which will be fully reinvested.
• Actions under the 2024 Restructuring Program are expected to be substantially completed by the end of 2031, resulting in cumulative annual net cost savings of approximately $750 million.
• Merck will vigorously contest the IRS Notices of Proposed Adjustment (NOPAs) through administrative and judicial proceedings.
• The Gardasil product liability trial in California state court is adjourned until February 2, 2026.
• The proposed agreement to substantially resolve Gardasil product liability litigation requires several conditions, including participation thresholds, to be met.
• Expert discovery on remaining alleged conditions and summary judgment briefing are to follow in the Gardasil MDL.
• A preliminary injunction hearing for subcutaneous pembrolizumab patent litigation in Germany is scheduled for December 4, 2025.
• Final Written Decisions for the remaining three JHU patents challenged by Merck are expected from the PTAB in mid to late November 2025.
• The district court stay for the Keytruda patent case is expected to continue until at least the issuance of Final Written Decisions for the three remaining patents.
• The Lynparza patent infringement trial is expected in 2026.
• Merck expects to continue the pace of share repurchases for the remainder of 2025.
• The EC decision on marketing authorization for Enflonsia is delayed, with Merck providing an update to the EMA and other health authorities in the near future.
• Results from the three Phase 3 CORALreef trials for MK-0616 will be presented at a future scientific congress.
• Merck plans to resubmit applications for marketing authorization in the EU and UK for Ohtuvayre at a future date.
• Timing for commercial availability of Winrevair in remaining EU countries is expected by the end of 2025.
• Timing of availability of Capvaxive in individual EU countries will depend on completion of reimbursement procedures.
• Merck anticipates that some international markets will experience supply constraints for ProQuad and Varivax during 2025 due to manufacturing delays.
• Merck will not make further Gardasil/Gardasil 9 shipments to China through at least the end of 2025.

Key Dates

Recommendation

Merck's Q3 2025 results demonstrate robust growth in key franchises like oncology (Keytruda) and cardiovascular (Winrevair), driving significant increases in net income and EPS. The company is actively managing its portfolio through strategic acquisitions (Verona Pharma) and a substantial restructuring program designed to generate significant cost savings and reinvest in growth areas. While facing patent expiries for Januvia and Gardasil sales challenges in China, Merck has proactively addressed legal risks (Gardasil settlement, Qui Tam/MMR II resolution, Bridion patent win) and is advancing a promising R&D pipeline, including new approvals like Enflonsia. The delay in Enflonsia's EC approval is a minor setback, and the IRS tax dispute is being vigorously contested. The overall picture is one of a well-managed pharmaceutical giant with strong core assets, a clear growth strategy, and effective risk mitigation, making it an attractive long-term investment.

Keywords

Pharmaceuticals, Biotechnology, Oncology, Vaccines, Animal Health, Keytruda, Gardasil, Januvia, Winrevair, Enflonsia, Restructuring, SEC Filing, 10-Q, Merck, Acquisitions, Drug Pricing, Patent Litigation, R&D Pipeline, COPD, HIV, RSV, Hyperlipidemia, Pulmonary Arterial Hypertension